Vol. 2 No. 4 (2022)
Reimbursement Reviews

Sacituzumab Govitecan (Trodelvy)

Published April 8, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses sacituzumab govitecan (Trodelvy) 180 mg lyophilized powder for solution for injection, for IV use.
  • Indication: For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior therapies, at least 1 of them for metastatic disease.